期刊文献+

7-[(2S)-2-羟甲基-4-氨基-1-吡咯烷基]氟喹诺酮类化合物的合成及体外抗菌活性 被引量:2

Synthesis and Antibacterial Activity of 7-[(2S)-2-Hydroxymethyl-4-aminopyrrolidin-1-yl]fluoroquinolone Derivatives
下载PDF
导出
摘要 用反式-L-羟脯氨酸经对甲苯磺酰氯保护、甲酯化、氧化、肟化、四氢铝锂还原、叔丁氧基羰基保护后脱除对甲苯磺酰保护基,与不同的氟喹诺酮中间体缩合,最后经脱除叔丁氧基羰基等反应得到目标物,结构经1HNMR和FAB-MS确证,并进行了体外抗菌活性试验。结果表明,除化合物13对供试的大部分菌株,特别是对链球菌的体外活性相当于或优于对照药加替沙星和环丙沙星外,其余3个目标物总体活性均低于对照品。 The novel target compounds 13 - 16 were synthesized from L-hydroxyproline by protection with TsCl,esterification, oxidiation, oximation, reduction, protection with (Boc)2O and then detosylation with Na-Hg amalgam to give(2S)-2-hydromethyl-4-(N-tert-butyoxylcarbonyl)aminopyrrolidine, which after hydrolysis, condensed with four quinoloneintermediates respectively to obtain 9 - 12. The antibacterial activity of 13 - 16 were tested in vitro against 10 Gram-positiveand 10 Gram-negative organisms. The compound 13(MIC 0.03 - 0.12mg/ml) showed better activity against Streptococcithan gatifloxacin(MIC 0.12 - 0.5mg/ml) and ciprofloxacin (MIC 0.5 - 2mg/ml). Compounds 14(MIC 0.25 - 16mg/ml) and15(MIC 0.25 - 64mg/ml) have moderate activity against all 20 organisms. The compound 16(MIC>64mg/ml) showed nosignificant activity against all 20 organisms.
机构地区 中国医学科学院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2005年第3期129-132,共4页 Chinese Journal of Pharmaceuticals
关键词 氟喹诺酮类抗菌剂 抗菌活性 合成 fluoroquinolone derivatives antibacterial activity synthesis
  • 相关文献

参考文献8

  • 1Hong CY, Kim YK, Lee YH, et al. Methyloxime-substituted aminopyrrolidine: a new surrogate for 7-basic group of quinolone [J]. Bioorg Med Chem Lett, 1998, 8 (3): 221-226.
  • 2Rosen T, Chu DTW, Lico IM, et al. Asymmetric synthesis and properties of the enantiomers of the antibacterial agent 7- (3-aminopyrrolidin- 1-yl) - 1- (2,4-difluorophenyl) - 1,4-dihydro-6-fluoro-4-oxo- 1,8-naphthyridine-3-carboxylic acid hydrochloride[J]. JMed Chem, 1988, 31 (8) : 1586-1590.
  • 3陈胜昔,郭惠元.新的广谱、高效喹诺酮类抗菌药gemifloxacin[J].国外医药(抗生素分册),2002,23(6):279-283. 被引量:11
  • 4Hong CY, Kim YK, Chang JH, et al. Novel fluoroquinolone antibacterial agents containing oxime-substituted(aminomethyl) pyrrolidines: synthesis and antibacterial activity of 7- (4- (aminomethyl)-3- (methoxyimino)pyrrolidin-1 -yl) - 1 -cyclopropyl-6- fluoro-4-oxo- 1,4-dihydro [ 1,8 ]naphthyridine-3-carboxylic acid (LB20304) [J]. J Med Chem,1997, 40 (22) : 3584-3593.
  • 5Yevich JP, Dextraze E Preparation of pyrimidylpiperazines as agents for treatment of brain and spinal cord ischemia [P]. EP:400661, 1990-12-05. (CA 1991, 114: 247309g).
  • 6Tronchet JMJ, Jorand C, Zosimo-Landolfo G, et al. Spin labeled hydroxyproline analogues [J]. Farmaco, 1999, 54 (9) :637-641.
  • 7Mich TF, Sanchez JP, Domagala JM, et al. 1-Cyclopropyl-6,8-difluoro- 1,4-dihydro-4-oxo-3-quinolinecarboxylic acids;1-cyclopropyl- 1,4-dihydro-6-fluoro-4- oxo- 1,8-naphthyridine-3-carboxylic acids and their derivatives [P]. EP: 153828, 1985-09-04. (CA 1986, 104: 88512t).
  • 8刘明亮,孙兰英,魏永刚,郭慧元.托氟沙星对甲苯磺酸盐的合成[J].中国医药工业杂志,2003,34(4):157-158. 被引量:7

二级参考文献25

  • 1[1]Morrissey I, George JT. Purification of pneumococcal type Ⅱ topoisomerases and inhibition by gemifloxacin and other quinolones. [J]. JAntimicrob Chemother, 2000, 45(Suppl S1):101
  • 2[2]Hardy D, Amsterdam D, Mandell LA, et al. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci. [J]. Antimicrob Agents Chemother, 2000, 44(2):802
  • 3[3]Cormican MG, Jones RN. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphyridone. [J]. Antimicrob Agents Chemother, 1997, 41(1): 200
  • 4[4]Goldstein EJC, Citron DM, Warren Y, et al. In vitro activity of gemifloxacin (SB 265805) against anaerobes. [J]. Anfimicrob Agents Chemother, 1999, 43(9): 2231-2235
  • 5[5]Dubois J, St-Pierre C. Comparative in vitro potency and post-antibiotic effect of gemifloxacin against Legionella spp. [J]. J Antimicrob Chemother, 2000, 45 (suppl. S1): 41
  • 6[6]Roblin PM, Reznik T, Kutlin A, et al. In vitro activities of gemifloxacin (SB 265805, LB20304) against recent chnical isolates of Chlamydia pneumoniae. [J]. Antimicrob Agents Chemother, 1999, 43(11):2806
  • 7[7]Oh JI, Paek KS, Ahn MJ, et al. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. [J]. Antimicrob Agents Chemother, 1996, 40(6): 156 4
  • 8[8]Berry V, Page R, Satterfield J, et al. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. [J]. J Antimicrob Chemother, 2000,45(Suppl S1):79
  • 9[9]Berry V, Page R, Satterfield J, et al. Comparative efficacy of gemifloxacinin experimental modes of pyelonephritis and wound infection. [J].J Antimicrob chemother, 2000,45(suppl s1): 87
  • 10[10]Dubois J, St-Pierre C. Comparative in vitro activity and post-antibiot ic effect of gemifloxacin against Legionella spp. [ J]. J Antimicrob Chemother, 2000, 45 (Suppl S1): 41

共引文献16

同被引文献27

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部